MTCR News and Press, Metacrine Inc.

Nasdaq said Wednesday it will delist shares of Waitr ( OTCQB:ASAP ), Calithera Biosciences ( OTC:CALA ), Statera Biopharma ( OTCPK:STAB ), Allied Healthcare Products ( OTC:AHPI ) and Tricida ( OTCPK:TCDAQ ). The exchange will also delist Eqonex ( OTCPK:EQOSQ ), Sco...

A Beginner’s Guide to Trading Penny Stocks Under $1 The stock market is a complex and ever-changing landscape. For investors looking to get in on the action, stocks trading for under $1 can present significant potential returns. But like anything else in the stock market today, there&#...

LA JOLLA, Calif., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR) and Equillium, Inc. today announced the mutual termination of their previously announced definitive merger agreement. Metacrine is continuing to evaluate all strategic opportunities. Additional information reg...

SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company developing differentiated therapies for patients with gastrointestinal diseases, today reported its third-quarter 2022 financial results. “We made great progre...

Summary Today, we circle back on Equillium for the first time in a year and a half. The company has several compounds in development, recently disclosed encouraging trial results and also executed a small strategic merger. An investment analysis follows in the paragraphs below...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Clinical-stage biotechnology firm Equillium (NASDAQ: EQ ), which focuses on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, released encouraging clinical data regarding itolizumab....

NEW YORK, NY / ACCESSWIRE / September 8, 2022 / Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Forma Therapeutics, Holdings Inc...

Equillium ( NASDAQ: EQ ) announced Tuesday the definitive deal to acquire Metacrine ( NASDAQ: MTCR ) in an all-stock transaction. The acquisition is estimated to add $33M in cash to Equillium’s balance sheet at closing, which is expected to ext...

Expected to add $33 million in cash at closing to Equillium’s balance sheet and extend operating runway into 2024 Acquisition includes novel drug candidate MET642, an orally delivered Phase 2 ready FXR agonist for ulcerative colitis Preston Klassen, M.D., MH...

Metacrine press release ( NASDAQ: MTCR ): Q2 Net loss was $6.3 million for the three months ended June 30, 2022, as compared to $15.6 million for prior-year period. Cash, cash equivalents and short-term investments were $55.5 million as of June 30, 2022. Fo...